Control Bionics Full Year 2025 Earnings: AU$0.023 loss per share (vs AU$0.037 loss in FY 2024)

Control Bionics (ASX:CBL) Full Year 2025 Results

Key Financial Results

• Revenue: AU$6.14m (up 15% from FY 2024).
• Net loss: AU$6.11m (loss widened by 3.3% from FY 2024).
• AU$0.023 loss per share.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the North America (US) segment contributing a total revenue of AU$5.68m (93% of total revenue). The largest operating expense was General & Administrative costs, amounting to AU$8.46m (83% of total expenses). Explore how CBL's revenue and expenses shape its earnings.

Control Bionics shares are up 5.7% from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with Control Bionics (including 3 which are potentially serious).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.